October 24, 2016
Genotype 2 accounts for about 9% of all hepatitis C infections worldwide. It is the most common type of infection in West Africa, although the greatest number of cases is in East Asia where it is less common but still represents a sizable percentage of all infections. In the United States, genotype 2 accounts for nearly 15% of infections.
In the prior era of peginterferon and ribavirin treatments, patients with genotype 2 infections were the easiest to treat. Today, even higher cure rates exist with new direct-acting antivirals. The best option is the one-pill combination of sofosbuvir/velpatasvir. An alternative is the combination of sofosbuvir and daclatasvir (Daklinza).
Credit: naruedom for iStock via Thinkstock.
Sony Salzman is a freelance journalist reporting on health care and medicine, who has won awards in both narrative writing and radio journalism. Follow Salzman on Twitter: @sonysalz.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|Conversations on Viral Suppression and HIV Transmission, Social Media and HIV, and an Update on PACHA From the 2017 U.S. Conference on AIDS|
|Guidance for Providers Treating HIV-Positive People Displaced by Hurricane Harvey|
|This Week in HIV Research: Injectable PrEP Shows Promise in New Study|
|Million in Funding to Help HIV Organizations Impacted by Hurricanes Harvey and Irma Announced at USCA|
|Heavy Marijuana Use Tied to Midlife Cardiovascular Events in U.S. Men With HIV|
|Conversations With Federal HIV Leaders From the 2017 U.S. Conference on AIDS|